Search

CN-122005766-A - Application of SCD1 in preparation of medicines for treating nerve myelin damage diseases

CN122005766ACN 122005766 ACN122005766 ACN 122005766ACN-122005766-A

Abstract

The application provides application of SCD1 in preparation of medicines for treating nerve myelin damage diseases, firstly reveals SCD1 as a brand new target for treating sciatic nerve myelin damage diseases, fills up the blank of the existing target lipid metabolism regulation myelin regeneration medicines, can realize omnibearing repair from molecular, morphological and functional aspects, on one hand, the SCD1 can up regulate PMP22, MPZ and other genes to express myelin synthesis from root, on the other hand, can increase myelin thickness, reduce the number of non-myelinated nerves, improve the structural integrity and stability of regenerated myelin, and meanwhile, the SCD1 can prolong stay time of a rotating rod, accelerate nerve conduction speed, improve dyskinesia and nerve conduction abnormality after sciatic nerve damage, and in addition, the application provides a novel strategy with high efficiency, stability and safety for clinical treatment of sciatic nerve myelin damage by regulating endogenous lipid metabolism as a core mechanism, safely and controllably, and repeatedly mature experimental system.

Inventors

  • DUAN XUCHU
  • ZHANG YANXIAN
  • LIU XIAOYU

Assignees

  • 南通大学

Dates

Publication Date
20260512
Application Date
20260325

Claims (10)

  1. 1. Application of stearoyl-CoA desaturase 1 (SCD 1) in preparing medicament for treating nerve myelin damage disease.
  2. 2. The use of SCD1 as claimed in claim 1 for preparing medicine for treating nerve myelin damage diseases, wherein the nerve myelin damage diseases are sciatic nerve myelin diseases.
  3. 3. The use of SCD1 as claimed in claim 2 for preparing a medicament for treating demyelinating diseases of nerve myelin, wherein the demyelinating diseases of sciatic nerve include sciatic nerve crush injury, compression injury and traumatic demyelination.
  4. 4. The use of SCD1 in the manufacture of a medicament for treating a neurological myelin damage disease according to claim 1, wherein the medicament promotes sciatic nerve remyelination and repair by over-expression of SCD1, and wherein the medicament is capable of ameliorating motor dysfunction following a myelin damage in sciatic nerves.
  5. 5. The use of SCD1 in the manufacture of a medicament for treating a neurological disorder of myelin damage according to claim 4, wherein improving motor dysfunction comprises increasing the residence time of the rotating rod and increasing the nerve conduction velocity.
  6. 6. The use of SCD1 in the manufacture of a medicament for treating a neurological myelin damage disease according to claim 1, wherein the medicament increases myelin thickness, reduces the number of non-myelinated nerves, and maintains the structural integrity of myelin.
  7. 7. The use of SCD1 as claimed in claim 1 for preparing a medicament for treating a neurological myelin damage disease, wherein the medicament can also up-regulate expression of myelin-associated genes PMP22, MPZ.
  8. 8. A medicament for treating sciatic nerve myelin damage is characterized by comprising an SCD1 over-expression vector, an SCD1 protein or an SCD1 expression activator.
  9. 9. The drug for treating sciatic nerve myelin damage according to claim 8, wherein the drug further comprises a pharmaceutically acceptable carrier, excipient or adjuvant.
  10. 10. The medicine for treating sciatic nerve myelin sheath injury according to claim 8, wherein the medicine is in the form of injection, freeze-dried powder injection or slow release preparation.

Description

Application of SCD1 in preparation of medicines for treating nerve myelin damage diseases Technical Field The application relates to the technical field of biomedicine, in particular to application of SCD1 in preparation of a medicament for treating nerve myelin damage diseases. Background The peripheral nervous system is responsible for connecting the central nervous system with peripheral target organs, and its structural and functional integrity is the basis of normal physiological activities of the body. The sciatic nerve is used as the thickest peripheral nerve of a human body, is easily damaged by factors such as trauma, compression, inflammation, metabolic disorder and the like, causes demyelination and axonal degeneration, further causes the Waler degeneration, has symptoms such as dyskinesia, paresthesia and the like, and seriously influences the life quality of patients. After injury of sciatic nerve myelin sheath, remyelination and nerve function repair are the key links of clinical treatment, but the clinic still lacks efficient and targeted therapeutic drugs and intervention means at present. Peripheral myelin is mainly formed by schwann cells, and its high lipid composition is key to myelin structure stabilization and normal function, and lipid metabolic disorders can directly block myelin synthesis and regeneration, promote inflammation, and further delay the nerve repair process. Therefore, the key target point for regulating and controlling the sciatic nerve myelin regeneration is discovered, the action mechanism is clear, and the development of the targeted therapeutic drug has important significance for the clinical treatment of the sciatic nerve myelin injury diseases. Disclosure of Invention The application aims to solve the technical problem that a key target for sciatic nerve myelination is lacked in the prior art. In order to achieve the above purpose, the present application provides the following technical solutions: Application of stearoyl-CoA desaturase 1 (SCD 1) in preparing medicament for treating nerve myelin damage disease. Preferably, the demyelinating diseases refer to sciatic demyelinating diseases. Preferably, the sciatic nerve myelin sheath diseases include sciatic nerve crush injury, compression injury, and traumatic myelin demyelination. Preferably, the agent promotes sciatic nerve remyelination and repair by over-expressing SCD1, and the agent is capable of ameliorating motor dysfunction following sciatic nerve myelin lesions. Preferably, the improvement of motor dysfunction includes an increase in the residence time of the rotating rod and an increase in nerve conduction velocity. Preferably, the agent is capable of increasing myelin thickness, decreasing the number of non-medullary nerves, and maintaining the structural integrity of myelin. Preferably, the agent may also up-regulate expression of myelin-associated genes PMP22, MPZ. The application also provides a medicament for treating sciatic nerve myelin damage, which comprises an SCD1 over-expression vector, an SCD1 protein or an SCD1 expression activator. Preferably, the medicament further comprises a pharmaceutically acceptable carrier, excipient or adjuvant. Preferably, the medicament is in the form of injection, freeze-dried powder injection or sustained release preparation. Compared with the prior art, the application at least comprises the following beneficial effects: 1. The invention proves that the SCD1 can be used as a key target point for repairing the sciatic nerve myelin sheath injury for the first time, fills the blank of no targeted lipid metabolism regulation sciatic nerve myelin sheath regeneration medicine in the prior art, and provides a brand new direction for sciatic nerve injury treatment. 2. The application proves that the over-expression of SCD1 obviously increases the thickness of myelin sheath, reduces the number of non-myelinated nerves, improves the structural integrity and stability of the regenerated myelin sheath, and morphologically accelerates the repair process after injury of sciatic nerve myelin sheath. 3. The application also proves that SCD1 can obviously prolong the stay time of the model mouse rotating rod, accelerate the nerve conduction speed, quickly relieve the movement dysfunction caused by the ischial nerve injury and promote the nerve conduction function recovery through a verification experiment. 4. The application also proves that SCD1 can obviously up-regulate the expression of myelin sheath key genes PMP22 and MPZ through verification experiments, and the molecular level drives myelin sheath synthesis and regeneration, and has definite action mechanism and stable effect. 5. The medicine provided by the application has clear action path, mature and repeatable experimental method, is convenient to develop into a targeted medicine and has good clinical application and industrialization prospect aiming at common types such as sciatic nerve crush injury, traumatic my